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The last 20 years have witnessed significant advances in
the field of epilepsy with a host of new diagnostic
descriptions and treatment options for the neurologist. In
this month’s journal club, we review 3 papers which
together provide a brief glimpse into an evolving innova-
tive approach to epilepsy and also address some common
dogmas in the nature and treatment of this common
condition.
Contemporary classification of the epilepsies has intro-
duced a new vocabulary to communicate between medical
staff and patients. In parallel the International League
Against Epilepsy (ILAE) has recently proposed a similar
redefinition and reclassification of status epilepticus (SE)
which is likely to have a significant effect on patient
management and is the focus of the first paper reviewed.
The second sets out to debunk one of the last held myths in
epilepsy: that a generalised epilepsy syndrome (now often
recognised to have a genetic cause) does not have associ-
ated architectural changes within the cortex. Finally, we
examine recent evidence that perampanel may have a role
in treating not only focal epilepsies but also in the
adjunctive treatment of patients with refractory generalised
seizures.
A definition and classification of status
epilepticus—report of the ILAE Task Force
on Classification of Status Epilepticus
A standardised definition of SE has long evaded medical
terminology with previous definitions relying on ambigu-
ous phrases including a seizure as a ‘‘fixed and enduring
condition’’, or one persisting for a ‘‘sufficient length of
time.’’ The authors of this paper have sought to provide a
new definition of SE, with a stated goal of providing a
structured terminology, but one which could evolve as
advances in neurobiology and pathophysiology became
apparent. The suggested terms consist of a time point (t1)
after which time a given seizure is considered to be ‘‘an
abnormally prolonged seizure’’, and a second time point
(t2) after which time neuronal injury is thought to occur.
This second time point provides a degree of impetus about
how aggressive one should be in treating an abnormally
prolonged seizure. The values of these time points vary
depending on underlying seizure type.
This new classification of SE involves four axes: the
semiology of the seizure, aetiology, EEG correlate, and the
age of the patient. The goals of reclassification are to
improve communication between healthcare professionals,
improve treatment of patients, permit epidemiological
studies, and guide basic research.
Comment. This paper follows on from the natural suc-
cess of the earlier redefinition and reclassification of the
epilepsies from the ILAE. However, it is important to stress
that the new definition, by their own admission, is based
upon incomplete evidence, and ‘‘considerable variation’’.
Whilst they have allowed for the advent of future knowl-
edge in the decision to include two time points, it may have
been simpler to adopt a new single approach with the
lowest common denominator. Classifying a generalised
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tonic–clonic seizure ‘abnormally prolonged’ after 5 min,
but a focal motor seizure ‘prolonged’ after 10 min might
appear pedantic since clinicians may not make this dis-
tinction in clinical practice. Furthermore, there may be
concerns in the suggested guidance that a treating clinician
has greater than 60 min before the onset of neuronal injury
since it may promote a delay in treatment as a result of a
perceived lack of urgency. Furthermore, in spite of these
specific time frames, the authors acknowledge that the
likelihood of damage is dependent on the location of the
epileptic focus the intensity of the status, and the age of the
patient.
The reclassification of SE provides a more reasoned
argument. Certainly, improved communication between
healthcare professionals is needed in the emergency set-
ting. However, this also highlights a limitation since it is
directed at an audience most accepting of the proposed
changes. It could be argued that the optimum target for
reclassification should be Emergency Physicians who are
more likely to encounter SE at presentation. Nevertheless,
this more accurate guide to the description, semiology and
aetiology of the seizure will undoubtedly aid management.
Less helpful in the acute management (but more so with
ongoing management) is an EEG correlate, an investigation
that may not always be provided in a timely fashion.
Trinka E et al. (2015) Epilepsia 56(10):1515–1523.
Cortical microarchitecture changes in genetic
epilepsy
The identification of genetic underpinnings of generalised
epilepsy has allowed for the development of animal models
of these epilepsies. This paper described the situation of a
GABAAc2(R43Q) mouse which replicates the human
phenotype of absence seizures with spike-and-wave dis-
charges, and reduced threshold to thermal seizures. A
pedigree with a pure febrile seizure phenotype was chosen
to determine the effect of this mutation on cortical devel-
opment. A labelled, viral vector was inserted into the tha-
lamus to aid in histological interpretation. A putative area
of cortex was studied against a control area in the
somatosensory cortex. The authors found an increased
density of GABAergic neurons, but also that the ratio
between excitatory and inhibitory GABAergic neurons was
reduced (suggesting that inhibitory neuron density alone
did not predict function). Additionally, changes in the
diversity of inhibitory neurons were seen at different cor-
tical layers, especially in layers associated with high levels
of expression of the c2 subunit during embryonic devel-
opment. This paper suggested that microscopic changes are
seen in specific areas of the cortex associated with a
specific model of a genetic generalised epilepsy.
Comment. This paper is an important first step in the
understanding of the effects of mutations on cortical
structures, and provides a springboard for future efforts and
replication. However, there are a number of limitations to
the paper itself: Firstly the SCN1A mutation is the more
well-characterised mutation but fails historically as a
mouse model. Secondly, the GABAAc2 mouse was used as
its own control for neuron density and type. Thirdly, the
area of cortex studied is not well developed in humans. It
would have been a useful adjunct to this paper, if mouse
MRI data were also included.
However, this paper does provide an interesting insight
suggesting that it is not solely inhibitory neuron density
that is responsible for changes in cortical excitability, but
perhaps the ratio with excitatory neurons. This may provide
an explanation of the differences seen in transcranial
magnetic stimulation excitability in different epilepsies.
Wimmer VC et al. (2015) Neurology 84:1308–1316.
Perampanel for tonic–clonic seizures in idiopathic
generalised epilepsy—a randomised trial
This paper reports a well-designed, multicentre, ran-
domised, placebo-controlled trial that demonstrates clear
efficacy for perampanel in the adjunctive management of
patients with refractory generalised epilepsy. The popula-
tion group and range of current medications was similar to
that in clinical practice. There was a 76.5 % reduction in
median seizure frequency in the treatment group, with a
greater than 50 % response rate seen in 64.2 % of the
treatment group. Complete seizure freedom was achieved
in 23.5 % of the treatment group. Adverse events (AE)
were comparable between the two groups, and serious AE
were only seen in a minority of patients, and were man-
ageable with medication withdrawal. One death occurred in
each group: SUDEP in the placebo arm, and an accidental
drowning in the treatment arm. No biochemical abnor-
malities were noted in either group. This paper provided
justification for inclusion of perampanel into the pharma-
copoeia for refractory generalised epilepsy.
Comment. This paper has built on the previous success
of three previous randomised, placebo-controlled trials in
the management of focal epilepsy. The study was well
designed but did include the inferior primary endpoint of
percent change in seizure frequency per 28 days, over the
more acceptable and widely used 50 % seizure responder
rate (although this was included as a secondary endpoint
for the purpose of registration according to European
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Union guidelines). A major strength of the study was the
rigorous screening that patients went through to ensure
they had idiopathic generalised epilepsy (now recognised
as a genetic epilepsy) on the basis of age at onset, EEG
data, MRI data, and seizure description. This allowed a
much stronger effect size to be seen, which the authors
point to when making comparisons with other benchmark
trials of efficacy in generalised epilepsy.
The drug was well tolerated and no unexpected AE were
identified. One SUDEP death amongst the placebo group
continues to raise concerns about the design of trials in
generalised epilepsy that have placebo arms, and how to
protect these at-risk patients. Earlier trials of perampanel
had allowed greater doses (up to 12 mg) that were not seen
in this paper (maximum 8 mg). The reason for this was not
stated.
The trial is now undergoing an open-label extension and
the results of this are eagerly awaited.
French JA et al. (2015) Neurology 85:950–957.
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